Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07KSG
|
||||
| Former ID |
DAP000108
|
||||
| Drug Name |
Tamoxifen
|
||||
| Synonyms |
Citofen; Crisafeno; Diemon; Istubol; Nourytam; Novaldex; Oncomox; Retaxim; Tamizam; Tamone; Tamoxen; Tamoxifene; Tamoxifeno;Tamoxifenum; Tomaxithen; Valodex; TRANS FORM OF TAMOXIFEN; Tamoxifen and its salts; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Tamoxifen (Z); Tamoxifen [INN:BAN]; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifenum [INN-Latin]; Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H29NO
|
||||
| InChI |
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
|
||||
| InChIKey |
NKANXQFJJICGDU-QPLCGJKRSA-N
|
||||
| CAS Number |
CAS 10540-29-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9319, 603542, 4266414, 7886804, 7980727, 8794645, 11113844, 14853108, 24900307, 26697206, 26752017, 26752018, 30091348, 46393636, 46487938, 46505515, 47213210, 47216564, 47364953, 47364954, 47364955, 47588786, 47662047, 47662048, 47662049, 47736233, 47959503, 48184778, 48258990, 48334237, 48427434, 49688681, 49698369, 49854602, 50104683, 50104684, 50104685, 50104686, 53789476, 56310641, 56310662, 56310717, 56310801, 56311275, 56311294, 56311693, 56311998, 56312239, 56312443, 56312444
|
||||
| ChEBI ID |
ChEBI:41774
|
||||
| SuperDrug ATC ID |
L02BA01
|
||||
| SuperDrug CAS ID |
cas=010540291
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Antagonist | [535410], [536925] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
| Ref 536863 | Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 1;113(9):2385-97. | ||||
| Ref 538623 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.